

# Hodgkin Lymphoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

**Biomarkers/Characteristics:** (select all that apply)

CD20 status: \_\_Negative \_\_Positive HIV associated lymphoma: \_\_No \_\_Yes Transplant Candidate: \_\_No \_\_Yes

## Classical Hodgkin Lymphoma | Early Stage (Stage I-IIA, Favorable and Unfavorable Risk)

\_\_\_ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT\*

## Classical Hodgkin Lymphoma | Advanced Stage (Stage IIB, III, and IV)

\_\_\_ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT\*

\*ISRT – Involved site radiation therapy

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 12/3/2019 | Effective date: 2/4/2019

Appropriate.Safe.Affordable

© 2020 AIM Specialty Health  
9012-0220